ICD 10 Codes >> Diseases of the respiratory system (J00-J99) J00-J99 >>Lung diseases due to external agents (J60-J70) J60-J70 >> Hypersensitivity pneumonitis due to organic dust J67.-

ICD 10 Code J67.4

Maltworker's lung

2017 Billable/Specific Code

A disease of the pulmonary system, caused by the fungi Aspergillus clavatus or Aspergillus fumigatus. This disease commonly presents with fever, chills, fatigue, weight loss, cough, headache, myalgia, or shortness of breath. Transmission is by inhalation of fungal spores. Confirmation is by identification of Aspergillus in a sputum, blood, or skin sample.
  • J67.4 is a billable ICD-10 medical codes that provide a detailed representation of a patient's conditions or diagnoses.
  • ICD-10-CM codes are used for a variety of purposes, including statistics and for billing and claims reimbursement.
  • This is the American ICD 10 CM Version Of J67.4 allows for the capture of data regarding signs, symptoms, risk factors and comorbidities to better describe the clinical issue overall.

    Inclusion Term For Icd 10 Code J67.4

    • Alveolitis due to Aspergillus clavatus

Reverse Index Lookup for ICD 10 CM CODE J67.4

The following ICD-10-CM Index entries contain back-references to ICD-10-CM J67.4:
  • Allergy, allergic   T78.40
    • alveolitis   J67.9
      • due to
        • Aspergillus clavatus   J67.4
    • due to
      • Aspergillus clavatus   J67.4
  • Maltworker\'s lung   J67.4
    • hypersensitivity   J67.9
      • maltworker\'s lung   J67.4

  • SNOMed Terms:
    • Alveolitis due to Aspergillus clavatus and fumigatus
    • Alveolitis due to Aspergillus clavatus AND/OR fumigatus
    • Malt fever
    • Malt house workers' cough
    • Malt workers lung
    • Malt workers' lung
    • Malt-workers' alveolitis
    • Malt-workers' lung
    • Malt-workers' lung (disorder)
    • Malt-workers' lung disease

    • Major Diagnostic Categories

      • MDC Category : 04
      • MDC Type : Medical
      • Description : Diseases and Disorders of the Respiratory System

    • Medicare Severity-Diagnosis Related Groups

      • DRG Range: 196-198

    • Clinical Classifications Software

      • CCS Category Number : 132
      • Description : Lung disease due to external agents
      • Multi CCS Level 1 Number : 8
      • Level 1 Description : Diseases of the respiratory system
      • Multi CCS Level 2 Number : 8.7
      • Level 2 Description : Lung disease due to external agents [132.]

    • Prevention Quality Indicators (admissions for 'ambulatory care sensitive conditions')

      J67.4 ICD CODE is not Assigned For ACSA Admit

    • New York University Emergency Department visit severity algorithm
      NYU ED

      Non-emergent - 0%
      Emergent/Primary Care Treatable - 0%
      Emergent - ED Care Needed - Preventable/Avoidable - 0%
      Emergent - ED Care Needed - Not Preventable/Avoidable - 0%
      Primary diagnosis of injury 0%
      Primary diagnosis of mental health problems 0%
      Primary diagnosis of substance abuse 0%
      Primary diagnosis of Alcohol 0%
      Unclassified 100%

    Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. The inflammation and scarring make it hard to get enough oxygen. The scarring is called pulmonary fibrosis.Breathing in dust or other particles in the air is responsible for some types of ...

    A Case of Adult Metastatic Rhabdomyosarcoma of the Prostate Cured by Long-Term Chemotherapy with Local Radiation.

    Konno M, Mitsuzuka K, Yamada S, Yamashita S, Kaiho Y, Ito A, Watanabe M, Arai Y

    MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy.

    Chen Y, Zhou X, Qiao J, Bao A

    The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

    Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM

    Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.

    Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y

    Feasibility and Acceptability of "Healthy Directions" a Lifestyle Intervention for Adults with Lung Cancer.

    Blok AC, Blonquist TM, Nayak MM, Somayaji D, Crouter SE, Hayman LL, Colson YL, Bueno R, Emmons KM, Cooley ME

    Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis.

    Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU

    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.

    Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon SD, Lip GYH, Lees KR, McMurray JJV,

    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.

    Bax JJ, Delgado V, Sogaard P, Singh JP, Abraham WT, Borer JS, Dickstein K, Gras D, Brugada J, Robertson M, Ford I, Krum H, Holzmeister J, Ruschitzka F, Gorcsan J

    Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study.

    Aaron CP, Hoffman EA, Lima JAC, Kawut SM, Bertoni AG, Vogel-Claussen J, Habibi M, Hueper K, Jacobs DR, Kalhan R, Michos ED, Post WS, Prince MR, Smith BM, Ambale-Venkatesh B, Liu CY, Zemrak F, Watson KE, Budoff M, Bluemke DA, Barr RG

    Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients.

    Cai G, Xiao F, Cheng C, Li Y, Amos CI, Whitfield ML

    Child Group Time: 0.83505988121033